The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 21, 2020

Filed:

Jan. 10, 2017
Applicant:

Zhejiang Jiachi Development Pharmaceuticals Ltd, Hangzhou, CN;

Inventors:

Jun Yang, Shandong, CN;

Wenping Xu, Shanghai, CN;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/40 (2006.01); A61P 35/00 (2006.01); A61K 31/444 (2006.01); A61K 31/506 (2006.01); A61K 31/517 (2006.01); A61K 31/519 (2006.01); A61K 31/5377 (2006.01); A61K 39/395 (2006.01);
U.S. Cl.
CPC ...
A61K 31/40 (2013.01); A61K 31/444 (2013.01); A61K 31/506 (2013.01); A61K 31/517 (2013.01); A61K 31/519 (2013.01); A61K 31/5377 (2013.01); A61K 39/3955 (2013.01); A61P 35/00 (2018.01); A61K 2300/00 (2013.01);
Abstract

The present invention found that lasofoxifene is an antagonist of ER-α36. It not only inhibits the growth of ER-α36 positive lung, colon and gastric cancers, and also it can inhibit the growth of acquired or de novo tamoxifen-resistant MCF-7 cells. Our finding also provides methods and compositions for treating cancer comprising lasofoxifene alone or in combination with at least one other agent selected from the group consisting of gefitinib and/or trastuzumab or functional equivalent thereof, and an inhibitor in hormonal or epidermal growth factor signal transduction pathways.


Find Patent Forward Citations

Loading…